Graft Function Assessment
Graft Function Assessment - Related Videos
09:29
Technique of Subnormothermic Ex Vivo Liver Perfusion for the Storage, Assessment, and Repair of Marginal Liver Grafts
0 Views •
Cited by 31 •
2014
Marginal grafts, such as fatty livers, grafts from older donors, or livers retrieved after cardiac death (DCD) tolerate conventional, cold static storage only poorly. We developed a novel model of subnormothermic ex vivo liver perfusion for preservation, assessment, and repair of marginal liver grafts prior to transplantation.
05:41
Non-invasive Assessment of Microvascular and Endothelial Function
0 Views •
Cited by 12 •
2013
Capillaroscopy is a non-invasive, relatively inexpensive methodology for directly visualizing the microcirculation. The forearm blood flow technique provides accepted non-invasive measures of endothelial function.
07:37
Mouse Models for Graft Arteriosclerosis
0 Views •
Cited by 17 •
2013
We describe protocols for our mouse graft arteriosclerois (GA) models which involve interposition of a mouse vessel segment into a recipient of the same inbred strain. By backcrossing additional genetic changes into the vessel donor, the model can assess the effect of specific genes on GA.
05:00
Using a Chemical Biopsy for Graft Quality Assessment
0 Views •
Cited by 11 •
2020
The protocol presents utilization of the chemical biopsy approach followed by comprehensive metabolomic and lipidomic analysis for quality assessment of kidney grafts allocated for transplantation.
11:31
Antigens Protected Functional Red Blood Cells By The Membrane Grafting Of Compact Hyperbranched Polyglycerols
0 Views •
Cited by 5 •
2013
The cell membrane modification of red blood cells (RBCs) with hyperbranched polyglycerol (HPG) is presented. Modified RBCs were characterized by aqueous two phase partitioning, osmotic fragility and complement mediated lysis. The camouflage of surface proteins and antigens was evaluated using the flow cytometry and Micro Typing System (MTS) blood phenotyping cards.
FAQs
Serial measurements show whether a transplanted organ or tissue is recovering, remaining stable, or changing over time. Establishing an early baseline allows later laboratory results, imaging findings, and clinical performance to be interpreted against the graft’s own postoperative pattern. This comparison helps clinicians recognize emerging dysfunction rather than mistaking expected recovery changes for complications.
These approaches assess complementary aspects of graft status. Clinical and laboratory findings indicate functional performance, imaging helps evaluate structural or anatomical changes, and biopsy provides tissue-level evidence when direct examination is needed. Considering the results together is more informative than relying on one measurement, particularly when dysfunction could reflect ischemia, infection, drug toxicity, or immune-mediated rejection.
Assessment supports differential interpretation by combining trends in graft performance with laboratory, imaging, and, when necessary, tissue findings. A change may reflect immune-mediated rejection, but ischemia, infection, or drug toxicity can produce clinically concerning abnormalities as well. Comparing results with the established baseline and the postoperative context helps guide the next diagnostic or therapeutic decision.
Monitoring begins with clinical evaluation and establishment of a post-transplant baseline, followed by repeated organ-specific laboratory measurements and appropriate imaging. Clinicians compare each result with prior findings to track recovery or detect deterioration. If the available evidence does not adequately explain a change, tissue biopsy may be added, allowing assessment to become more structurally specific.
A biopsy may be considered when clinical findings, laboratory measurements, and imaging do not sufficiently explain suspected graft dysfunction or structural injury. It supplies direct tissue information that complements noninvasive assessment and can help evaluate concern for immune-mediated rejection. Because biopsy is used when necessary rather than automatically, its role depends on the unresolved clinical question.
In clinical care, the findings help determine whether immunosuppressive management or other interventions should change, while also supporting evaluation of long-term graft survival. In research, repeated functional, laboratory, imaging, and biopsy outcomes provide objective measures for comparing recovery, complications, and durability. The same assessment framework therefore links individual patient management with standardized transplant outcomes.